Novel antitrypanosomal agents

Steverding, Dietmar and Tyler, Kevin M. ORCID: https://orcid.org/0000-0002-0647-8158 (2005) Novel antitrypanosomal agents. Expert Opinion on Investigational Drugs, 14 (8). pp. 939-955. ISSN 1354-3784

Full text not available from this repository. (Request a copy)

Abstract

Trypanosomes are the causative agents of Chagas' disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas' disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity.

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User: EPrints Services
Date Deposited: 25 Nov 2010 11:08
Last Modified: 19 Oct 2023 00:55
URI: https://ueaeprints.uea.ac.uk/id/eprint/11503
DOI: 10.1517/13543784.14.8.939

Actions (login required)

View Item View Item